Differences in δ- and μ-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects
The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Blockade of brain mu-opioid receptor (mu-OR) and delta-opioid receptor (delta-OR) was investigated in recently abstinent alcohol-dependent subjects (N=21) maintained on naltrexone. Subjects completed a 19-day inpatient protocol, which included alcohol abstinence followed by naltrexone treatment (50 mg) on days 15-19. Blood samples were collected after the first administration of naltrexone to evaluate serum levels of naltrexone and 6-beta-naltrexol. Regional brain mu-OR binding potential (BP) and delta-OR Ki was measured using [11C]carfentanil (CAR) positron emission tomography (PET) and [11C]methyl naltrindole ([11C]MeNTI) PET, respectively, before (day 5) and during naltrexone treatment (day 18). Naltrexone inhibition of [11C]CAR BP was near maximal across all brain regions of interest with little variability across subjects (mean+SD% inhibition=94.9+4.9%). Naltrexone only partially inhibited the [11C]MeNTI Ki and there was more variability across subjects (mean+SD% inhibition=21.1+14.49%). Peak serum levels of naltrexone were positively correlated with % inhibition of delta-OR Ki in neocortex and basal ganglia. Peak serum levels of naltrexone were not correlated with % inhibition of mu-OR BP. Peak levels of 6-beta-naltrexol were not significantly correlated with % inhibition of mu-OR BP or delta-OR Ki. Thus, the FDA recommended therapeutic dose of naltrexone was sufficient to produce near complete inhibition of the mu-OR in recently abstinent alcohol dependent subjects. The lower percent inhibition of delta-OR and greater variability in delta-OR blockade by naltrexone across subjects may contribute to individual differences in treatment outcomes to naltrexone. Further investigations on the relationship between individual differences in delta-OR blockade by naltrexone and clinical outcomes should be explored.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“following steady-state oral administration, naltrexone achieves approximately 95% mu opioid receptor occupancy”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [122]
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Subjects completed the Clinical Institute Withdrawal Assessment-Alcohol Revised (CIWA-Ar) (Sullivan et al, 1989), 3–4 times each day for the first 5 days.”
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Bucholz, K. K., Cadoret, R., Cloninger, C. R., Dinwiddie, S. H., Hesselbrock, V. M., Nurnberger, J. I., Reich, T., Schmidt, I., & Schuckit, M. A. (1994) · Journal of Studies on Alcohol · doi:10.15288/jsa.1994.55.149 · Cited by 1,757
Davis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Alcohol dependence syndrome: Measurement and validation.
Skinner, H. A., & Allen, B. A. (1982) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.91.3.199 · Cited by 1,061
Research works printed but not linked: 1
- Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL et al (1996). Imaging of delta opioid receptors in human brain by N1′- ([11C]methyl)naltrindole and PET. Synapse 24: 19–28. · DOI · Paper page
Cited by
Items 101–144 of 144
Peters, K. B., Affronti, M. L., Woodring, S., Lipp, E., Healy, P. N., Herndon, J. E., Miller, E., Freeman, M. W., Randazzo, D. M., Desjardins, A., et al. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06738-0 · Cited by 7
Human Brain Imaging of Opioid Receptors
Ghitza, U. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00004-x · Cited by 7
Therapeutic uses of Cannabis sativa L. Current state and future perspectives
Fraguas‐Sánchez, A. I., & Torres‐Suárez, A. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89867-6.00010-x · Cited by 7
Spencer, C. N., Elton, A., Dove, S., Faulkner, M. L., Robinson, D. L., & Boettiger, C. A. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100085 · Cited by 6
The Utilization of Low Dose Naltrexone for Chronic Pain
Poliwoda, S., Noss, B., Truong, G. T., Creech, Z. A., Koushik, S. S., Urits, I., & Viswanath, O. (2023) · CNS Drugs · doi:10.1007/s40263-023-01018-3 · Cited by 6
Effects of genotype and food on naltrexone exposure in adolescents
Stancil, S. L., Voss, M. M., Nolte, W. M., Tumberger, J., Adelman, W. P., & Abdel‐Rahman, S. M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13399 · Cited by 6
Molecular Imaging Studies of Alcohol Use Disorder
Bach, P., de Timary, P., Gründer, G., & Cumming, P. D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_414 · Cited by 8
Evaluation of advanced, pathophysiologic new targets for imaging of CNS
Singh, P., Singh, D., Srivastava, P., Mishra, G., & Tiwari, A. K. (2023) · Drug Development Research · doi:10.1002/ddr.22040 · Cited by 5
Molecular Imaging to Biomarker Development in Neuroscience
Frost, J. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.027 · Cited by 5
Self-citationShifting the sociometer: opioid receptor blockade lowers self-esteem
Tchalova, K., Béland, S., Chanda, M. L., Levitin, D. J., & Bartz, J. A. (2023) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsad017 · Cited by 7
Castillo, F., Harris, H. M., Lerman, D., Bisaga, A. M., Nunes, E. V., Zhang, Z., Wall, M. M., & Comer, S. D. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001247 · Cited by 4
Low-dose naltrexone extends healthspan and lifespan in C. elegans via SKN-1 activation
Li, W., McIntyre, R. L., Schomakers, B. V., Kamble, R., Luesink, A. H. G., van Weeghel, M., Houtkooper, R. H., Gao, A. W., & Janssens, G. E. (2024) · iScience · doi:10.1016/j.isci.2024.109949 · Cited by 4
A Novel Maintenance Therapeutic for Opioid Use Disorder
Youngblood, B. D., Li, K. D., Gehlert, D. R., Medina, J. C., & Schwartz, N. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000214 · Cited by 6
de Moura, F. C., Xavier, M. K. F., Rodrigues, F. E. L., Pinheiro, M. F. D. S., Machado, E. C. L., Moura, C. B. C. D., de Moraes, W. M. A. M., Prestes, J., & Chaves, E. M. C. (2019) · World Scientific Research · doi:10.20448/journal.510.2019.61.5.13 · Cited by 5
Neurochemical Imaging of Addictive Disorders
Broft, A. I., & Martínez, D. (2012) · Neuromethods · doi:10.1007/7657_2012_48 · Cited by 6
How to Study Smoking and Drinking with PET
Evan, D., Molly, V., & Kelly, P. (2013) · InTech eBooks · doi:10.5772/57414 · Cited by 5
Positron Emission Tomography (PET) Imaging of Opioid Receptors
van Waarde, A., Absalom, A. R., Visser, A. K. D., & Dierckx, R. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_20 · Cited by 3
Potential uses of naltrexone in emergency department patients with opioid use disorder
Bradley, E. S., Liss, D. B., Carreiro, S., Brush, D. E., & Babu, K. M. (2019) · Clinical Toxicology · doi:10.1080/15563650.2019.1583342 · Cited by 4
Kitamura, A., Higuchi, K., Kurosawa, T., Okura, T., Kubo, Y., & Deguchi, Y. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00347 · Cited by 3
Choubey, A., Kar, A. K., Girdhar, K., Chattopadhyay, T., Dogra, S., Kushwaha, S., Medhi, B., Bhansali, A. K., Mantri, C. K., Kolthur‐Seetharam, U., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/705103 · Cited by 3
Treatment of compulsive sexual behavior disorder (CSBD) with a naltrexone implant: A case report
Liu, L., Tian, X., & Zhou, X. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104686 · Cited by 2
Femenía, T., Portillo, P. A., Pérez‐Ortiz, J. M., Aracil-Fernández, A., Rubio, G., & Manzanares, J. (2009) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523800902020053 · Cited by 2
Roche, D. J. O., Trela, C. J., Argos, M., Jasmine, F., Kibriya, M. G., Ahsan, H., & King, A. C. (2019) · Alcohol and Alcoholism · doi:10.1093/alcalc/agz046 · Cited by 2
Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them
Banks, M. L. (2026) · CNS Drugs · doi:10.1007/s40263-026-01300-0 · Cited by 1
Carter, A. C. (2015) · Cited by 1
The State of Opioid Medication Assisted Treatment (MAT)
Stanciu, C. N. (2018) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000e141 · Cited by 1
Ross, L. P., Andreescu, C., & Inagaki, T. K. (2021) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000986 · Cited by 2
Positron Emission Tomography (PET) Imaging of Opioid Receptors
van Waarde, A., Absalom, A. R., Visser, A. K. D., & Dierckx, R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_21 · Cited by 1
THE EFFECT OF NALTREXONE ON NICOTINE-INDUCED CONDITIONED PLACE PREFERENCE IN RATS
Adams, J. M. (2014) · Cited by 1
PET IMAGING OF THE PHARMACOKINETICS OF SMALL MOLECULAR‐WEIGHT DRUGS
Moerlein, S. M., & Tu, Z. (2013) · Wiley eBooks · doi:10.1002/9781118356845.ch7
Bart, G. B. (2013) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
potential: preliminary findings in human subjects
Weerts, E. M., McCaul, M. E., Kuwabara, H., Yang, X., Xu, X., Dannals, R. F., Frost, J. J., Wong, D. F., & Wand, G. S. (2013)
Self-citationReporter Gene Imaging of Cell Signal Transduction
Massoud, T. F., Paulmurugan, R., Chan, C. T., Fan-Minogue, H., & Gambhir, S. S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730405.009
Dania, I. A., & Novziransyah, N. (2021) · Jurnal Kedokteran Ibnu Nafis · doi:10.30743/jkin.v9i2.58
Acute Pain Management in Patients with Opioid Dependence
Kitt, A., & Kim, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-77399-1_10
The Effect of Opioid Blockade on Pain in Healthy Humans: A Systematic Review and Meta-Analysis
Jensen, E. N. (2021) · NVA (Nasjonalt vitenarkiv)
Fulton, B. S. (2014) · Wiley eBooks · doi:10.1002/9781118943670.refs
Naltrexone: New Dosages and Uses for Pain and Inflammation
Swidan, S. Z., & Frost, E. A. M. (2022) · Topics in Pain Management · doi:10.1097/01.tpm.0000872668.35151.10
The role of naltrexone and novel preparations for substance abuse and pain management
Tolj, V., Kaye, A. D., Robinson, C. L., Pokuri, S., & Maqbool, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26504-4.00012-0
Eaton-Fitch, N., Preez, S. D., Cabanas, H., Muraki, K., Staines, D., & Marshall-Gradisnik, S. (2022) · Figshare · doi:10.6084/m9.figshare.19185616
Primary Care Physicians’ Difficulty in Managing Patients with Alcohol Use Disorder: A Review Article
Tanie, T., Kanda, K., & Fujikawa, H. (2025) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2025.155031
Meier, I. M., Trøstheim, M., Jensen, E. N., Roland, M. N., Løseth, G. E., Eikemo, M., & Leknes, S. (2026) · Pain · doi:10.1097/j.pain.0000000000004097 · Cited by 1
Liang, C.-W., Lee, Y., & Wang, J.-K. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002261
Metadata
- Authors
- Weerts, E. M., Kim, Y. K., Wand, G. S., Dannals, R. F., Lee, J. S., Frost, J. J., & McCaul, M. E.
- Affiliations
- Johns Hopkins University (US)
- Seoul National University (KR)
- Corresponding author
- Weerts, Elise M
- Venue
- Neuropsychopharmacology
- Published
- 2007-05-09
- Volume
- 33
- Issue
- 3
- Pages
- 653-665
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2154071856
- Cited by
- 147
- References
- 93
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 9 · 2019: 15 · 2018: 9 · 2017: 2 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 7 · 2012: 14
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (AA11855, R01AA011855, R37AA012303, AA12303, AA11872, R01AA011872)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- naltrexone, mu-opioid receptor, delta opioid receptor, opioid receptor blockade, alcoholism, alcohol abstinence, [11C]carfentanil, individual differences in treatment response, brain receptor binding
- MeSH terms
- Adult, Alcoholism, Analgesics, Opioid, Data Interpretation, Statistical, Female, Fentanyl, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Substance Withdrawal Syndrome, Temperance, Receptors, Opioid, mu, Receptors, Opioid, delta, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.